<?xml version='1.0' encoding='utf-8'?>
<document id="24057042"><sentence text="Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528."><entity charOffset="44-53" id="DDI-PubMed.24057042.s1.e0" text="lapatinib" /><entity charOffset="90-100" id="DDI-PubMed.24057042.s1.e1" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.24057042.s1.e0" e2="DDI-PubMed.24057042.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24057042.s1.e0" e2="DDI-PubMed.24057042.s1.e1" /></sentence><sentence text="Everolimus, an oral inhibitor of mammalian target of rapamycin, can augment the efficacy of HER inhibitors in preclinical studies"><entity charOffset="0-10" id="DDI-PubMed.24057042.s2.e0" text="Everolimus" /><entity charOffset="53-62" id="DDI-PubMed.24057042.s2.e1" text="rapamycin" /><pair ddi="false" e1="DDI-PubMed.24057042.s2.e0" e2="DDI-PubMed.24057042.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24057042.s2.e0" e2="DDI-PubMed.24057042.s2.e1" /></sentence><sentence text=" This study was conducted to determine the safety and pharmacokinetics (PK) of the combination of lapatinib, a Her1 and 2 inhibitor, and everolimus and to describe its anti-tumor activity in the Phase I setting"><entity charOffset="98-107" id="DDI-PubMed.24057042.s3.e0" text="lapatinib" /><entity charOffset="137-147" id="DDI-PubMed.24057042.s3.e1" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.24057042.s3.e0" e2="DDI-PubMed.24057042.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24057042.s3.e0" e2="DDI-PubMed.24057042.s3.e1" /></sentence><sentence text="" /><sentence text="In Part I, dose escalation to define the maximum tolerated dose (MTD) was performed" /><sentence text=" In Part II, PK of both drugs were analyzed to assess drug-drug interaction" /><sentence text="" /><sentence text="Twenty-three evaluable patients with advanced cancers were treated on six different dose levels in Part I of the study" /><sentence text=" The dose-limiting toxicities were diarrhea, rash, mucositis, and fatigue" /><sentence text=" The MTD of the combination was 1,250 mg of lapatinib and 5 mg of everolimus once daily"><entity charOffset="44-53" id="DDI-PubMed.24057042.s10.e0" text="lapatinib" /><entity charOffset="66-76" id="DDI-PubMed.24057042.s10.e1" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.24057042.s10.e0" e2="DDI-PubMed.24057042.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24057042.s10.e0" e2="DDI-PubMed.24057042.s10.e1" /></sentence><sentence text=" In Part II of the study, 54 patients were treated with the combination at the MTD" /><sentence text=" The mean everolimus time to maximum concentration was increased by 44 %, and mean clearance was decreased by 25 % when co-administered with lapatinib, though these differences were not statistically significant"><entity charOffset="10-20" id="DDI-PubMed.24057042.s12.e0" text="everolimus" /><entity charOffset="141-150" id="DDI-PubMed.24057042.s12.e1" text="lapatinib" /><pair ddi="false" e1="DDI-PubMed.24057042.s12.e0" e2="DDI-PubMed.24057042.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24057042.s12.e0" e2="DDI-PubMed.24057042.s12.e1" /></sentence><sentence text=" There was no significant influence on the PK of lapatinib by everolimus"><entity charOffset="49-58" id="DDI-PubMed.24057042.s13.e0" text="lapatinib" /><entity charOffset="62-72" id="DDI-PubMed.24057042.s13.e1" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.24057042.s13.e0" e2="DDI-PubMed.24057042.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24057042.s13.e0" e2="DDI-PubMed.24057042.s13.e1" /></sentence><sentence text=" Two patients achieved a partial response [thymic cancer (45+ months) and breast cancer (unconfirmed PR; 7 months)]; 11 patients attained stable disease of at least 4 months" /><sentence text="" /><sentence text="Lapatinib and everolimus are well tolerated at doses of 1,250 and 5 mg po daily, respectively"><entity charOffset="0-9" id="DDI-PubMed.24057042.s16.e0" text="Lapatinib" /><entity charOffset="14-24" id="DDI-PubMed.24057042.s16.e1" text="everolimus" /><pair ddi="false" e1="DDI-PubMed.24057042.s16.e0" e2="DDI-PubMed.24057042.s16.e0" /><pair ddi="false" e1="DDI-PubMed.24057042.s16.e0" e2="DDI-PubMed.24057042.s16.e1" /></sentence><sentence text=" Stable disease â‰¥4 months/PR was achieved in 13 of 78 patients (17 %)" /><sentence text="" /></document>